Q3 Revenue Jumps 29,567% to $642,889 as AI Nose Orders Convert to Sales
AIMD has more than doubled off its 52-week low of $0.434 on elevated volume (3.1× avg).
Summary
Ainos posted Q3 2026 revenue of $642,889, up 29,567% year over year, driven by the one-time $600,000 VELDONA license fee and AI Nose semiconductor revenue. GAAP net loss narrowed 36% and gross margin expanded to 83.4% from 78.0%, while operating expense fell 20.3%. The company delivered 1,400 AI Nose systems under its $2.1 million agreement and expects roughly $175,000 in recurring revenue per quarter from that deal starting in Q4. After quarter-end it collected $950,000 in contractual payments and has a $4.5 million initial payment due within 60 days under the previously announced $9 million ASE follow-on order. Its $11 million convertible notes payable became a current liability as of September 30, 2026, and the company has begun discussions to address notes due in 2027. The numbers are a real step up from the near-zero revenue and going-concern footing in the last 10-Q, but the base is tiny and the recurring revenue is modest relative to the loss run rate. Watch whether the $4.5 million ASE payment lands within the 60-day window and how the 2027 convertible notes are addressed.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Ainos' $11 million convertible notes payable became a current liability as of September 30, 2026, and the company has begun discussions to address notes due in 2027.
At the time of this announcement, AIMD was trading at $1.30 on NASDAQ in the Technology sector, with a market capitalization of approximately $10.7M. The 52-week trading range was $0.43 to $3.88. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.